Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Así es como usted puede verificarlo

Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.

Los sitios web seguros .gov usan HTTPS
Un candado (  ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

La información sobre este estudio está en inglés.

Si necesita ayuda en español, comuníquese con el Centro de Educación y Referencias sobre la Enfermedad de Alzheimer y las Demencias Relacionadas (ADEAR, por sus siglas en inglés) por teléfono al 800-438-4380 o envíe un correo electrónico. También puede llamar o enviar un correo electrónico al contacto del estudio (en inglés) para obtener información adicional.

Find more clinical trials

Online Caregiver Training for Rural Dementia Caregivers in Appalachian Kentucky

Start: January 2022
End: December 2022
Enrollment: 40

What Is This Study About?

This study, called Harmony at Home, will examine the effectiveness of an online caregiver training program to reduce caregiver stress and improve caregiver satisfaction and sense of control. The program teaches caregivers to make changes in their home environment (e.g., lighting, noise level, temperature) and access features (e.g., stairs, bathrooms) to improve access and support positive behavior changes in the person living with dementia. Caregivers of people with moderate-to-severe dementia living in the Appalachian region of rural Kentucky will receive training, using videoconferencing, from an occupational therapist once a week for six weeks. At the start and end of the training period, and at a one-month follow-up, participants will complete questionnaires to report their sense of personal control, caregiver burden, stress, and satisfaction, as well as behavioral symptoms of the person living with dementia.

Do I Qualify To Participate in This Study?

Minimum Age: 21 Years

Maximum Age: 99 Years

Must have:

Caregivers:

  • Access and ability to use video technology for telehealth visits
  • Able to speak, read, and write in English
  • Able to retrieve and return mail

Participants with Alzheimer's disease:

  • Age 65 or older
  • Living at home with a primary caregiver
  • Diagnosis of Alzheimer's disease with a Clinical Dementia Rating Scale score > 1
  • No changes in any medical condition for at least one month prior to screening visit
  • No changes in medications within four weeks prior to study screening
  • If taking psychotropic medication, dosage and treatment must be stable for the duration of the study
  • Overall good physical health, based on a physical exam and laboratory tests
  • Able to hear, see, smell, touch, and taste, with or without sensory aids
  • Challenging behaviors, as reported by the caregiver, within four weeks of starting study
  • Previous contact with a doctor or other medical provider at the University of Kentucky Alzheimer's Disease Research Center or the Kentucky Neuroscience Institute within one year of starting study

Must NOT have:

Caregivers:

  • Diagnosis of mild cognitive impairment or dementia
  • Severe psychological stress or current psychiatric conditions (e.g., severe depression, mania, hallucinations, or delusions)

Participants with Alzheimer's disease:

  • Any serious or unstable medical conditions within one month prior to screening visit (e.g., poorly controlled blood pressure, diabetes, current cancer diagnosis, major infection, breathing problems)
  • Diagnosis of serious sensory altering disorder that could interfere with study (e.g., macular degeneration, legal blindness, total deafness, severe peripheral neuropathy, loss of smell)
  • Living in a nursing home or other long-term care facility
  • Wheelchair or bed bound
  • Skin lesions or skin abnormalities on hands or arms
  • Allergies to lotion or fragrance
  • Physically violent behaviors, as reported by caregiver
  • Started an antipsychotic medication within four weeks of study screening
  • Major depression or other mental illness such as schizophrenia, bipolar disorder, personality disorders, or substance abuse within the past year
  • Seizures with or without a diagnosis of epilepsy
  • Participation in another clinical trial or treatment with any experimental drug within one month prior to study screening
  • Major infection within four weeks prior to starting the study
  • Participation, expected or unexpected, in physical or occupational therapy during study duration

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Allison Gibson

Source: ClinicalTrials.gov ID: NCT05202223

alzheimers.gov/es

Un sitio web oficial del Gobierno de los Estados Unidos, gestionado por el Instituto Nacional sobre el Envejecimiento, parte de los Institutos Nacionales de la Salud